The Liver Meeting 2024 - Debrief Sessions - Portuguese-Heptacellular Carcinoma Debrief Session

Video Transcription

Video Summary

Dr. Nihar Parikh from the University of Michigan discussed recent advancements in hepatocellular carcinoma (HCC) research. He covered topics like risk prediction, surveillance, prognosis, and treatment. For risk prediction, novel genetic variants associated with cirrhosis and HCC were identified, enabling better patient stratification. A study focused on non-cirrhotic HCC revealed significant genetic heterogeneity, highlighting TERT polymorphisms' role. In surveillance, lowering the AFP threshold for HCC screening in certain liver disease contexts showed potential for increased sensitivity. A novel surveillance method using extracellular vesicles evidenced promising early results. Dr. David Goldberg's work on prognosis developed an objective method to predict survival, outperforming traditional BCLC staging based on subjective criteria. In treatment, the STRIDE regimen for Child-Pugh B patients demonstrated safety but limited efficacy. The LEAP012 trial indicated improved progression-free survival (PFS) with a combination of Linvatinib, Pembrolizumab, and TACE but raised concerns about serious adverse effects. Overall, these studies represent progress in understanding and managing HCC.

Keywords

hepatocellular carcinoma

genetic variants

surveillance methods

prognosis prediction

treatment advancements